Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
Authors
Keywords
<em class=EmphasisTypeItalic >HER2</em> mutation, Lung adenocarcinoma, Pemetrexed
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-04
DOI
10.1186/s12885-018-4277-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas
- (2017) Chien-Hung Gow et al. GENES CHROMOSOMES & CANCER
- Clinical outcomes with pemetrexed-based systemic therapies inRET-rearranged lung cancers
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
- (2016) Xuefei Li et al. BMC CANCER
- HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
- (2016) Bob T. Li et al. Journal of Thoracic Oncology
- Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations
- (2016) Yen-Fu Chen et al. Journal of Thoracic Oncology
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCR
- (2016) Yan Wang et al. LUNG CANCER
- Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers
- (2016) Juliana Eng et al. LUNG CANCER
- Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort
- (2015) J. Mazières et al. ANNALS OF ONCOLOGY
- Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
- (2015) M. G. Kris et al. ANNALS OF ONCOLOGY
- EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer
- (2015) Yan Wang et al. Journal of Thoracic Oncology
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors
- (2013) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Association ofEGFRmutation orALKrearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma
- (2012) Shengxiang Ren et al. CANCER
- Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma
- (2012) Shengxiang Ren et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
- (2011) Jeong-Ok Lee et al. Journal of Thoracic Oncology
- Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
- (2011) Chenguang Li et al. PLoS One
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started